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Abstract
The non-toxic C-terminal fragment of the tetanus toxin (TTC) has been described as a neuroprotective molecule since it 
binds to Trk receptors and activates Trk-dependent signaling, activating neuronal survival pathways and inhibiting apop-
tosis. Previous in vivo studies have demonstrated the ability of this molecule to increase mice survival, inhibit apoptosis 
and regulate autophagy in murine models of neurodegenerative diseases such as amyotrophic lateral sclerosis and spinal 
muscular atrophy. Prion diseases are fatal neurodegenerative disorders in which the main pathogenic event is the conversion 
of the cellular prion protein  (PrPC) into an abnormal and misfolded isoform known as  PrPSc. These diseases share different 
pathological features with other neurodegenerative diseases, such as amyotrophic lateral sclerosis, Parkinson’s disease or 
Alzheimer’s disease. Hitherto, there are no effective therapies to treat prion diseases. Here, we present a pilot study to test 
the therapeutic potential of TTC to treat prion diseases. C57BL6 wild-type mice and the transgenic mice Tg338, which over-
express  PrPC, were intracerebrally inoculated with scrapie prions and then subjected to a treatment consisting of repeated 
intramuscular injections of TTC. Our results indicate that TTC displays neuroprotective effects in the murine models of 
prion disease reducing apoptosis, regulating autophagy and therefore increasing neuronal survival, although TTC did not 
increase survival time in these models.
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Introduction
Transmissible spongiform encephalopathies (TSEs), also 
termed prion diseases, are fatal neurodegenerative disor-
ders caused by prions that affect humans and a wide vari-
ety of animal species [1]. These diseases share, as the main 
pathogenic event, the conversion of the cellular prion protein 
 (PrPC) into an abnormal and misfolded isoform known as 
 PrPSc. This leads to the accumulation of  PrPSc in the central 
nervous system (CNS), which causes neuronal dysfunction 
and cell death [2]. TSEs show morphological and patho-
physiological hallmarks that mirror those of other neuro-
degenerative diseases, such as amyotrophic lateral sclerosis 
(ALS), Alzheimer’s disease or Parkinson’s disease [3].
Neurodegeneration is the main pathological feature of 
prion diseases. Although molecular mechanisms involved in 
the pathogenesis of prion diseases are still unknown, several 
pathways have been proposed to play an important role in 
TSE-associated neurodegeneration, among which autophagy 
and apoptosis are particularly relevant [4].
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Autophagy is an essential mechanism of cellular catabo-
lism in which damaged components, such as misfolded pro-
teins, are included in double-membrane structures, known as 
autophagosomes, and degraded by lysosomes hence main-
taining homeostatic balance inside cells [5]. Thus, the acti-
vation of autophagic mechanisms seems to play a protective 
role since it can efficiently degrade misfolded proteins [6], 
and many studies have shown its importance in different 
neurodegenerative disorders like amyotrophic lateral scle-
rosis, Alzheimer’s disease or Parkinson’s disease, in which 
the presence of abnormal protein aggregates is a common 
feature [7]. In prion diseases, it has been observed that the 
impairment of autophagic mechanisms pharmacologically 
or by siRNA inhibits the capacity of cells to degrade  PrPSc 
[6]. Many studies have identified autophagic dysregulation 
in TSE models [4, 8–11], including the model used in this 
study [12] and impaired protein homeostasis has been impli-
cated as an important major cause of toxicity common to 
prion diseases [13]. Autophagic mechanisms, originated as 
a survival response to intracellular  PrPSc accumulation, can 
fail to recover homeostasis after exposure to  PrPSc, thus lead-
ing to neuronal dysfunction and cell death [14].
The activation of pro-apoptotic pathways has been dem-
onstrated in natural forms of prion disease [15]. These 
mechanisms have proven to be a common cause of neuronal 
cell death in animal TSEs in different studies of scrapie-
infected sheep, mice and hamsters [16, 17]. They have also 
been reported as a common form of neuronal death in human 
prion diseases as Creutzfeldt-Jakob disease (CJD) and fatal 
familial insomnia (FFI) [18]. Although its role is still con-
troversial, apoptosis in prion diseases has been linked to 
the up-regulation of the pro-apoptotic factor BAX (BCL2 
associated X) [19, 20]. Apoptosis can also be induced by 
chronic endoplasmic reticulum stress, which could activate 
pro-apoptotic pathways, such as IRE1 (inositol-requiring 
enzyme 1), ATF6 (activating transcription factor 6) or Akt/
PI3K (protein kinase B/phosphatidylinositol 3-kinase). All 
of them are related to the chaperone BiP/GRP78 (binding 
immunoglobulin protein), reported to be overexpressed in 
this kind of diseases [21]. Moreover, prion protein has been 
directly linked to apoptosis since  PrPSc aggregates have been 
associated with activation of caspase 3 and caspase 8 pro-
teins, triggering caspase-dependent pathways and resulting 
in apoptosis [22].
Tetanus neurotoxin (TeNT), a protein produced by 
Clostridium tetani, is the causative agent of tetanus, a 
potentially fatal condition [23]. TeNT toxicity depends on 
the presence of an L chain with metalloprotease activity 
[24], but its targeting to the neuronal synapses relies only 
on a 50 kDa carboxy-terminal non-toxic fragment known 
as TTC which is not only required but sufficient for neuron 
binding and internalization [25], retrograde transport and 
transsynaptic transport [26]. Hence, TTC has been used for 
targeting therapeutic molecules to the CNS [27], and several 
molecules such as the insulin-like growth factor 1 (IGF-1), 
the glial-derived neurotrophic factor (GDNF) or the brain-
derived neurotrophic factor (BDNF), among others, have 
been successfully transported into neurons by linking them 
to TTC [28–30].
Moreover, further studies have shown that TTC is more 
than a carrier, and it also has neurotrophic properties. TTC 
mimics the action of natural neurotrophic ligands by bind-
ing to Trk receptors and activating Trk-dependent signal-
ing, which leads to the activation of neuronal survival 
pathways and apoptosis inhibition [31]. Even though the 
detailed mechanism on how TTC activates Trk receptors is 
not known, activation of neuroprotective pathways by TTC 
binding to these receptors has been demonstrated in both 
in vivo and in vitro studies [32, 33]. TTC alone delays the 
onset of symptoms and functional deficits in ALS murine 
models, decreasing motoneuron death and prolonging mice 
lifespan [30, 34] and in mouse models of spinal muscular 
atrophy (SMA), where it modulates autophagy markers and 
reduces apoptosis [35].
The aim of the present study was to test TTC as a poten-
tial therapy for prion diseases. Considering the impact 
of autophagy and apoptosis in both prion diseases [36] 
and ALS [34, 37], in which TTC has shown therapeutic 
results, and the potential of TTC as an anti-apoptotic and 
autophagy-regulator molecule, we assessed the apoptotic 
and autophagic mechanisms in the CNS of prion diseased 
murine models treated with TTC.
Materials and Methods
Murine clinical Assay
Two models of mice were used: C57BL6 (expressing the 
wild-type variant of murine  PrPc) and Tg338 transgenic mice 
(overexpressing ~ 8 × the VRQ variant of ovine  PrPC) [38]. 
Twenty-four animals of the Tg338 mouse line were intrac-
erebrally inoculated with a second passage of sheep scrapie 
in Tg338, while twelve C57BL6 mice were intracerebrally 
challenged with the scrapie strain 22L.
Each mouse line was separated into two different groups: 
a control group (Tg338 n = 12; C57BL6 n = 6) and a treated 
group (Tg338 n = 12; C57BL6 n = 6). The treated group 
was intramuscularly inoculated with 1 µg of TTC recom-
binant protein [39] in the quadriceps muscle once a month, 
for 6 months, while the control group was intramuscularly 
inoculated with PBS following the same pattern. Groups 
were sex-balanced, with approximately half males and half 
females in all of them. Following the experimental design 
performed in previously published assays with TTC in neu-
rodegenerative diseases [34, 39], no negative controls (prion 
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uninfected mice, treated and untreated) were included since 
no neurodegeneration was supposed to appear at the ages 
the animals were sacrificed, and therefore no TTC-related 
effects were expected.
Mice were monitored daily for the onset of neurological 
signs. All animals were humanely euthanized by cervical 
dislocation when clinical signs of disease were detected (i.e. 
locomotor disorders, poor body condition and any signs of 
impaired feeding ability), and their brains collected. Brains 
were sagittally divided into two, and half of the brain was 
preserved in formaldehyde for its further use in histopatho-
logical and immunohistochemical analyses, while the other 
half was divided in two parts, one containing the frontal 
cortex, which was preserved frozen for further biomolecu-
lar analyses, and the other containing the rest of the areas, 
which was collected in RNAlater™ Solution for its use in 
gene expression analyses. No significant signs of distress or 
pain were observed in the animals other than those related 
to the onset of neurological signs, at which time they were 
euthanized. Kaplan–Meier survival curves were drawn and 
statistically significant differences in survival curves were 
assessed with the Mantel–Cox log-rank test (p < 0.05).
Histological and Immunohistochemical Analyses
The presence and distribution of  PrPSc in mouse brain sam-
ples was evaluated by paraffin-embedded tissue-blot (PET-
blot). PET-blot was performed as described elsewhere [40]. 
Briefly, 4-μm paraffin-embedded brain sections were col-
lected onto a nitrocellulose membrane and dried at 56 °C 
for 24 h. Membranes were then subjected to dewaxing and 
rehydration and incubated for 2 h in a proteinase K solution 
(250 μg/ml) at 56 °C to completely digest  PrPC. Denatura-
tion of the remaining  PrPres was achieved by incubating the 
membranes in a solution of guanidine thiocyanate 3 M. After 
blocking the membrane with 0.2% BSA to avoid cross-reac-
tivity, detection was carried out through sequential incuba-
tion with the anti-PrP antibody Sha31 (1:8,000, SPI-Bio) 
and a secondary alkaline phosphatase-conjugated antibody 
(1:500, Dako Agilent, Santa Clara, CA, USA), followed by 
development with NBT/BCIP (Thermo Fisher Scientific, 
Waltham, MA, USA).
To perform immunohistochemical and histopathological 
studies, sagittal sections from paraffin-embedded mouse 
brains (4 μm thick) were cut and collected on glass slides 
and dried at 56 °C for 24 h. Immunohistochemistry was 
used for the detection of NeuN, the activated (cleaved) form 
of caspase-3, LC3B and p62 to assess neuronal survival, 
apoptosis, and autophagic mechanisms, respectively. Anti-
gen retrieval was performed with citrate buffer (pH 6.0) 
for 10 min at 96 °C, and endogenous peroxidase activ-
ity was blocked using a blocking reagent (Dako Agilent) 
for 15 min. Next, sections were incubated with primary 
antibodies anti-LC3B (1:200; Santa Cruz Biotechnology, 
Dallas, TX, USA, sc-271625), anti-p62 (1:200; Enzo Life 
Sciences, PW9860) and anti-NeuN (1:100, Abcam, Cam-
bridge, UK, ab104224) during 1 h at room temperature and 
anti-caspase-3 (1:50; Santa Cruz Biotechnology, sc-56052) 
overnight at 4 °C. Then, samples were incubated with an 
enzyme-conjugated Envision polymer (Dako Agilent) for 
30 min at room temperature and DAB (diaminobenzidine, 
Dako Agilent) was used as the chromogen. For each marker, 
all animals were stained in a single batch in order to reduce 
possible staining intensity differences due to the immuno-
histochemistry performance. The specificity of the immu-
nohistochemical technique was determined by the absence 
of immunostaining in mouse brain sections in which the 
primary antibody incubation was omitted.
Neuropathological changes and spongiform lesions were 
studied by hematoxylin–eosin staining.
Brain sections were examined using a Zeiss Axioskop 40 
optical microscope. Evaluation was blindly performed in all 
animals, in nine encephalic areas : frontal cortex (Fc), septal 
area/striatum (Sa), Parietal cortex (Pc), hippocampus (Hc), 
thalamus (Th), hypothalamus (Ht), mesencephalon (Mes), 
medulla oblongata (Mobl) and cerebellum (Cbl) [41]. The 
cerebellum was not evaluated for LC3B, p62 and NeuN 
immunohistochemistry since no immunostaining was found 
in this area. Spongiosis and  PrPSc deposition were semi-
quantitatively scored on a scale of 0 (lack of spongiosis/
PrPSc deposit) to 5 (very intense spongiosis/PrPSc deposit) 
since semiquantitative evaluation is the standard method to 
assess these features [42]. Semiquantitative evaluation for 
spongiosis and PrPSc was performed twice for each mouse 
and brain area. Caspase-3 staining was quantitatively evalu-
ated by counting all the stained cells present in the whole 
sagittal section of each mouse brain at a 20 × magnification. 
LC3B, p62 and NeuN immunostaining was assessed using 
the Image J software. The Image J assessed markers stain-
ing was evaluated by the colour deconvolution method as 
previously described [43], which measures both the number 
of stained cells and the intensity at once. Two photographs 
(taken at 10 × magnification) of each brain area per mouse 
were evaluated. The used chromogen in the immunohisto-
chemistry techniques was diaminobenzidine (DAB), and 
therefore the images were subjected to colour deconvolution 
using the “H DAB” algorithm, and the “Colour_2” image 
(showing the DAB staining) intensity colour was measured 
by the “Mean gray value”. Once the mean gray value for 
each photograph was obtained, the resulting intensity val-
ues were converted to optical density by using the follow-
ing formula: OD = log(maximum intensity/mean intensity), 
therefore quantifying the average darkness of the image 
due to DAB signal. Since empty areas within the image can 
bias the results reducing the average OD, only photographs 
in which tissue occupied the whole area were analysed. 
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Statistically significant differences were determined using 
the Mann–Whitney U test (p < 0.05).
Western Blot Analyses
Briefly, 25 μg of total protein from the frontal cortex of 
four mice per group were subjected to 10% SDS/PAGE and 
transferred to PVDF membranes (Bio-Rad, Hercules, CA, 
USA). After blocking at 4 °C overnight with 2% bovine 
serum albumin (Thermo Fisher Scientific), the membranes 
were incubated for 1 h at RT with the following primary 
antibodies diluted in blocking buffer: mouse monoclonal anti 
MAP-LC3B (1:1000; Santa Cruz Biotechnology, sc-271625) 
and rabbit polyclonal anti p62 (1:1000, Enzo Life Sciences, 
PW9860). Next, the membranes were incubated for 1 h at RT 
with a HRP conjugated secondary antibody diluted 1:4000 
in blocking buffer (goat anti-mouse IgGHRP for MAP-LC3, 
or goat anti-rabbit IgG-HRP for p62; Santa Cruz Biotechnol-
ogy). After washing, Western blots were developed using 
the ECL Plus Western Blotting system (GE Healthcare, UK) 
and visualized with VersaDoc imaging system (Bio-Rad). 
After detection of the interest protein, β-actin immunodetec-
tion was also performed in both membranes to normalize 
band intensity quantification. Membranes were washed with 
PBST for 1 h at room temperature and then incubated with 
mouse monoclonal anti β-actin antibody (1:2000, Bio-Rad, 
VMA00048) for 2 h at room temperature and developed as 
described above.
The image J software was also used to quantify band 
intensity in Western blots. For this purpose, each band was 
individually selected and circumscribed with the rectangular 
ROI (region of interest) selection and then “Gels” function 
was used, obtaining the corresponding histograms for each 
band. This was followed by quantification of the peak area 
of intensity of the histograms. Obtained values were normal-
ized through the measure of the intensity of β-actin bands. 
Statistically significant differences were determined using 
the Student’s t test (p < 0.05).
Gene Expression Analyses
Four genes described to be involved in autophagy were 
selected for the analysis of their expression profile in the 
brain of mice: Atg5 (autophagy related 5), Becn1 (Beclin 1), 
Fbxw7 (F-box/WD repeat-containing protein 7) and Gas5 
(growth arrest-specific 5). Gene expression was quantified 
in the thalamic area (including thalamus, hypothalamus and 
the surrounding area) of mice since it showed a high accu-
mulation of  PrPSc and high scores of spongiform changes in 
both mouse models.
Sagittally cut sections of the thalamic area (thalamus, 
hypothalamus and surrounding area) were collected in 
RNAlater™ Solution (Thermo Fisher Scientific). Total 
RNA was obtained from 80 mg of this area using an RNeasy 
Lipid Tissue Mini kit (QIAGEN®, Venlo, the Netherlands) 
and following the manufacturer’s recommended protocol. 
Complementary DNA (cDNA) was obtained from 200 ng 
of total RNA using qScript™ cDNA Supermix (Quanta 
Biosciences™, Beverly, MA, USA). Resulting cDNA was 
diluted 1:5 in water for further analyses. The quantitative 
real-time polymerase chain reaction (qRT-PCR) was per-
formed with TaqMan probes (Thermo Fisher Scientific) used 
for the amplification of the selected genes. PCR reactions 
were performed using TaqMan Universal PCR Master Mix 
(Thermo Fisher Scientific), and PCR was carried out in a 
StepOne Real-Time PCR System (Thermo Fisher Scientific) 
using universal conditions. All reactions were run in trip-
licate in a total volume of 5 μL, using 2.25 μL of diluted 
cDNA. The expression of two housekeeping genes (H6pd, 
Sdha) was used to normalize results. Relative gene expres-
sion quantification was subsequently determined using 
normalized data and relative quantification was performed 
using the  2−ddCt method. Differences between experimen-
tal groups were evaluated using an unpaired Student’s t test 
(two-tailed), with significance at p < 0.05.
Results
Survival Time, Histopathological Lesions and  PrPSc 
Deposition Do Not Significantly Variate After 
Intramuscular Injection of TTC in Prion  Infected 
Mice
All mice were sacrificed at the onset of clinical signs. 
Signs of disease in C57BL6 included severe ataxia and 
poor body condition, while Tg338 showed slight locomotor 
disorders, kyphosis and poor body condition. For C57BL6 
mice, the mean survival time for the treated group (n = 6) 
was 164 ± 7 days, while for the control group (n = 6) was 
157 ± 4 days. Regarding Tg338 mice, mean survival times 
were 192 ± 12  days for the treated group (n = 12) and 
176 ± 16 days for the control group (n = 12). Although sur-
vival time means were higher for the treated group in both 
Tg338 and C57BL6, no significant differences between 
treated and control mice survival periods were found in any 
of the mouse lines when applying the Mantel-Cox log-rank 
test (Fig. 1).
Regarding prion-associated neuropathology, all mice of 
each line displayed similar neuropathological lesion pro-
files and  PrPSc deposition patterns, despite belonging to the 
treated or control group.
Spongiosis, the main histopathological lesion in prion 
diseases, was semiquantitatively evaluated in nine brain 
areas of all groups of mice on a scale from 0, meaning an 
absence of vacuolization, to 5, meaning intense spongiosis 
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(Fig. 2A). Spongiform changes were mostly observed in 
the neuropil rather than in neurons. C57BL6 mice showed 
higher spongiform changes in cerebellum and thalamus, 
while in Tg338 mice the most severe lesions were observed 
in medulla oblongata, thalamus, hippocampus, parietal 
cortex and septal area/striatum (Fig. 2B). Although treated 
mice seemed to display slightly lower lesion degrees in some 
brain areas in both C57BL6 and Tg338 mouse lines, no sig-
nificant differences were found between the treated and con-
trol groups in any of the lines.
Concerning  PrPSc deposits, evaluated by PET-Blot and 
semiquantitative scoring, C5BL6 mice showed higher 
deposition at the cerebellum, cortex, thalamus and hypo-
thalamus, while in Tg338 mice deposition profiles were 
characterized by peak scores at the hypothalamus, thala-
mus, mesencephalon and medulla oblongata (Fig. 3A). 
Deposition scores were similar in control and TTC-treated 
mice, and no statistically significant changes were detected 
comparing groups of each mouse line in any of the brain 
areas (Fig. 3B).
Fig. 1  Effect of TTC injection 
in the survival of prion-infected 
mice. Figure shows Kaplan–
Meier survival curves for 
C57BL6 mice and Tg338 mice. 
The Mantel–Cox log-rank test 
revealed no significant differ-
ences between groups
Fig. 2  Spongiform changes in 
the brains of TTC-injected and 
control Tg338 and C57BL6 
mice. A Representative images 
of hematoxylin and eosin 
staining in the hypothalamus of 
clinical prion-infected C57BL6 
and Tg338 mice. B Graph-
ics show comparisons of the 
semiquantitative evaluation (on 
a scale of 0, lack of spongiosis, 
to 5, very intense spongiosis) 
of these lesions in TTC-
injected and control groups of 
both mouse lines in medulla 
oblongata (Mobl), cerebellum 
(Cbl), mesencephalon (Mes), 
hypothalamus (Ht), thalamus 
(Th), hippocampus (Hc), septal 
area/striatum (Sa), Parietal cor-
tex (Pc) and frontal cortex (Fc). 
Spongiosis levels are similar in 
the control and treated groups. 
No significant differences were 




The Pro‑apoptotic Activated Form of Caspase‑3 Is 
Reduced in TTC‑Treated Mice with a Clinical Prion 
Disease
Immunohistochemical assessment of the active form of cas-
pase-3 revealed an increase of apoptotic processes in non-
treated mice compared to TTC-injected animals. Caspase-3 
immunostaining revealed isolated immunopositive neurons 
scattered throughout the brain. Apoptotic nuclei were also 
observed in some stained cells. Stained neurons were quan-
tified and the treated animals, both in line C57BL6 and in 
line Tg338, presented a significant lower number of apop-
totic cells (Fig. 4). When statistically compared with the 
Mann–Whitney U test, significant differences were found 
between the TTC-treated and control group in both mouse 
lines.
Mice Treated with Intramuscular Injections of TTC 
Show Differential Regulation of Autophagy Markers 
in the Brain Compared to Controls
LC3B and p62 proteins were immunohistochemically eval-
uated in order to determine whether the injection of TTC 
influenced the regulation of autophagy in prion diseases. 
Immunohistochemical determination of these two autophagy 
markers revealed differential regulation of autophagic 
mechanisms in mice treated with TTC injection. Regarding 
LC3B, an increase of immunolabelling was noticed in all 
brain areas of both C57BL6 and Tg338 TTC-treated mice 
compared to their controls (Fig. 5B). This difference was sta-
tistically significant after performing the Mann–Whitney U 
test in mesencephalon, hypothalamus, thalamus and parietal 
cortex in C57BL6 mice and in all the evaluated brain areas 
except the hippocampus in Tg338 mice. LC3B immunostain-
ing pattern was defined by consistent intraneuronal labeling 
affecting most of the neurons and by diffuse staining of the 
neuropil. Although they showed the same pattern, the con-
trol groups displayed a lower number of stained cells along 
with lower immunostaining intensities (Fig. 5A).
On the contrary, treated mice of both lines showed clearly 
lower accumulation of p62 in comparison to their respective 
controls. TTC-injected mice displayed lower immunostain-
ing scores in all the CNS analysed areas in both mouse 
lines. Differences were significant in medulla oblongata, 
hypothalamus, thalamus, frontal cortex and parietal cortex 
in C57BL6 mice and, as in LC3B evaluation, all brain areas 
but the hippocampus in Tg338 mice (Fig. 6B). The immu-
nolabeling for p62 was characterized by neuronal and glial 
intracellular staining and granular staining of the neuropil. 
All mice presented this pattern, but treated mice showed 
lesser staining intensities and a lower number of stained cells 
(Fig. 6A).
Fig. 3  PrPSc deposition in the 
brains of Tg338 and C57BL6 
mice TTC-injected and 
control groups. A Representa-
tive images of  PrPSc deposits 
detected by PET-blot method in 
the brain of C57BL6 and Tg338 
mice. B Graphics show com-
parisons of the semiquantitative 
evaluation (on a scale of 0, lack 
of staining, to 5, staining pre-
sent at maximum intensity) of 
these deposits in TTC-injected 
and control groups of Tg338 
and C57BL6 mice in medulla 
oblongata (Mobl), cerebellum 
(Cbl), mesencephalon (Mes), 
hypothalamus (Ht), thalamus 
(Th), hippocampus (Hc), septal 
area/striatum (Sa), Parietal cor-
tex (Pc) and frontal cortex (Fc). 
Mice belonging to each of the 
lines showed similar deposition 
scores. No significant differ-
ences of  PrPSc deposition were 




The specificity of the antibodies and protein expression 
of these two autophagy markers were also tested by West-
ern Blot in the frontal cortex of both treated and untreated 
C57BL6 and Tg338 mice. LC3B immunoblot revealed two 
bands at ~ 18 kDa and ~ 15 kDa, corresponding to the lipi-
dated and non-lipidated forms of this protein (Fig. 5C). After 
signal band quantification of the interest proteins and nor-
malization of the results by β-actin quantification, signifi-
cant differences were found in the Tg338 line, where treated 
mice displayed higher protein levels than the control group, 
in agreement with the results of the immunohistochem-
istry. Regarding p62 immunoblot analyses, a single band 
at ~ 62 kDa was detected (Fig. 6C), and significant differ-
ences were found for Tg338 mice, the control group showing 
higher expression levels of this protein than treated animals, 
also in accordance with the immunohistochemical analyses 
for this protein.
Four markers of autophagy (Atg5, Becn1, Fbxw7 and Gas 
5) were analysed by real-time PCR in mice brain samples 
to determine their mRNA expression levels after TTC treat-
ment. Expression of these genes was studied in the thalamic 
area (thalamus and hypothalamus) of Tg338 and C57BL6 
TTC-treated and control mice. Figure 7 displays the mean 
dCt values of the analysed genes. Becn1, Fbxw7 and Gas5 
displayed an upregulation and Atg5 was downregulated in 
treated C57BL6 mice (Fig. 7A). Differences in gene expres-
sion between TTC-treated and control mice were more 
remarkable in C57BL6 mice, where Atg5 displayed a sig-
nificant decrease of the expression (p = 0.02), while Becn1 
and Fbxw7 showed a significant upregulation (p = 0.0042 
and p = 0.0043, respectively) in the treated group. Significant 
changes were not detected in Tg338 mice (Fig. 7B).
Neuronal Survival Assessed Through NeuN Marker 
Expression Is Higher in Prion Diseased Mice Treated 
with TTC 
The NeuN protein is widely used to assess neuronal sur-
vival since it reflects the functional state of these cells. 
NeuN immunolabeling was observed as a strong immuno-
labeling of the nucleus along with a perinuclear staining 
affecting numerous cells (Fig. 8A). Treated mice from both 
lines showed increased neuronal survival in all the analysed 
brain areas since the control group of both lines displayed 
Fig. 4  Caspase-3 expression 
levels in CNS are higher in 
control mice than in TTC-
treated mice. A Caspase-3 
immunopositive cells (arrows) 
in the central nervous system 
of mice. B Graphics show the 
quantitative determination of 
caspase-3 stained cells in the 
brains of treated and control 
groups of C57BL6 and Tg338 
mice. Both mouse lines showed 
a lower number of immunoposi-
tive cells in the treated group, 
and significant differences 
appeared between groups when 
testing them with the Mann–






a lower number of immunolabeled neurons (Fig. 8). In 
C57BL6 mice, significant differences were found using the 
Mann–Whitney U test between the treated and control group 
in the septal area/striatum, while in Tg338 mice significant 
differences in NeuN expression appeared in all the analysed 
brain areas but the hippocampus (Fig. 8B).
Discussion
Prion diseases are fatal neurodegenerative disorders in which 
the main pathogenic event is the conversion of  PrPC into 
 PrPSc, leading to the accumulation of  PrPSc in the central 
nervous system and therefore causing neuronal dysfunction 
and death resulting in spongiform degeneration. The neu-
roprotective role of the non-toxic C-terminal fragment of 
tetanus toxin has been related to antiapoptotic and pro-sur-
vival pathways, resembling neurotrophins, and demonstrated 
in vitro [32, 44] and in vivo in murine models of ALS and 
SMA [30, 34, 35]. We report here the first assay with TTC 
in a model of prion-related neurodegeneration.
The role of apoptosis in prion-associated neurodegen-
eration is still unclear. This mechanism has been described 
in scrapie-infected mice several times [16, 17, 45, 46], and 
the activation of caspases and some alterations in apopto-
sis-related genes have been detected in the latest stages of 
human and animal prion diseases [15, 20, 47]. Despite this, 
when challenging knock-out mice for the pro-apoptotic pro-
teins caspase-12 or Bax with prions, no significant patho-
genic changes or disease progression were found [48, 49]. 
Hence, it has been suggested that in these diseases, apopto-
sis may not be especially important for the onset and pro-
gression of the disease but a late process or, alternatively, 
that the main cell death mechanism in prion diseases might 
involve a non-apoptotic pathway [14].
TTC has been described as an anti-apoptotic molecule 
that binds to Trk receptors activating Trk-dependent 
signaling. This leads to the activation of pro-survival 
pathways such as MAPK/ERK and PI-3 K, which inhibit 
caspase-dependent apoptosis [31]. Reduction of apoptosis 
due to this molecule has already been described in ALS 
murine models, where decreased levels of the active form 
of caspase-3 after TTC injection have been reported [34]. 
In this study, we have observed that TTC also reduces 
caspase-3 related apoptosis in prion-infected mice. TTC 
treated-mice presented significantly lower levels of the 
active form of caspase-3 in their brains, thus confirming 
that, as in other neurodegenerative diseases, TTC could 
affect antiapoptotic pathways.
The cellular process of autophagy has several functions 
within we find response to nutrient starvation, intracel-
lular clearance or elimination of pathogens [50], and it 
is also involved in the degradation of damaged proteins 
therefore being one of the most important protein home-
ostasis systems [5]. These functions make autophagy a 
pro-survival mechanism, but it has also been reported to 
mediate a non-apoptotic cellular death [51]. Due to this, 
the impairment of autophagy has been related to different 
pathologies, including neurodegenerative diseases [52]. 
Impaired protein homeostasis has been reported as one 
of the main causes of prion-associated toxicity [13], and 
autophagy has been claimed to have a neuroprotective role 
against prion-mediated neurotoxicity [13, 53, 54]. Despite 
its initial cytoprotective role, it has also been proposed 
that when autophagy progresses unrestrained over a cer-
tain threshold, it might lead to the upregulation of cell 
death markers and activation of apoptosis or other cell 
death modalities [55].
The analysis of LC3 (microtubule-associated protein 
1 light chain 3, which presents three isoforms — LC3A, 
LC3B and LC3C — and is present in the autophagosome 
membrane [56]) and p62 (also known as SQSTM1, seques-
tosome 1, which acts as a substrate in autophagic degrada-
tion [57]) together is a good approach for the evaluation 
of autophagic activity [58]. LC3B is one of the most used 
markers to monitor autophagy in mammals [59], and p62 
accumulation reveals a dysregulation of autophagic mecha-
nisms [60]. Moreover, the downregulation of LC3B and the 
accumulation of p62 have been reported in prion-infected 
clinical mice compared to non-diseased mice, suggesting 
an impairment of autophagy at the late stage of prion infec-
tion [12]. In our study, after TTC-injection, scrapie-diseased 
mice presented differences in the regulation of autophagy 
proteins compared to their controls. While LC3B showed 
an increase of immunolabelling in TTC-treated mice, p62 
immunostaining intensity was lower in this group compared 
to their controls, which reflects an induction of autophagy as 
a result of this treatment. These differences were present in 
all the analysed brain areas, and in both Tg338 and C57BL6 
mice.
Fig. 5  LC3B determination in Tg338 and C57BL6 prion infected 
mice after TTC intramuscular injection. A Different staining levels 
of LC3B immunostaining found in mice cerebral cortex, showing a 
cytoplasmic staining in neurons. B Comparison of the evaluation 
through Image J software of the LC3B immunostaining in TTC-
injected and control groups of Tg338 and C57BL6 lines in medulla 
oblongata (Mobl), mesencephalon (Mes), hypothalamus (Ht), 
thalamus (Th), hippocampus (Hc), septal area/striatum (Sa), pari-
etal cortex (Pc) and frontal cortex (Fc). Treated mice of both lines 
show higher LC3B accumulation. Significant differences were stud-
ied using the Mann–Whitney U test (*p < 0.05 and **p < 0.01) and 
found in Mes, Ht, Th and Pc in C57BL6 mice and in Mobl, Mes, Ht, 
Th, Pc, Sa and Fc in Tg338 mice. C Western Blot analyses of LC3B 
in the frontal cortex of the four groups of mice. Distinctive bands 
at ~ 18 kDa and ~ 15 kDa, corresponding to the lipidated and non-lipi-
dated forms of LC3B. β-Actin immunodetection is shown at ~ 42 kDa. 
Significant differences were found between treated and untreated 






To complement the autophagic-related protein expression 
studies, we assessed the autophagy at a gene-expression level 
through the analysis of the markers of autophagy Becn1, 
Fbxw7, Gas5 and Atg5 [36]. After injection of TTC, we 
observed an upregulation of Becn1, Fbxw7 and Gas5 and a 
downregulation of Atg5 transcripts. Downregulation of these 
positive autophagy gene regulators (Becn1, Fbxw7, Gas5 
and Atg5) has been described in the CNS of scrapie-infected 
mice (both wild-type or transgenic) and naturally scrapie 
infected sheep [12, 61]. Therefore, the observed upregula-
tion of Becn1, Fbxw7 and Gas5 could reflect a recovery 
of autophagy dysregulation induced by prions after TTC 
injection. Gene expression differences were more noticeable 
in C57BL6 mice than in Tg338 mice.  PrPC seems to play a 
role in the regulation of the autophagic process [62], and 
then overexpression of ovine  PrPC in Tg338 could affect 
autophagy modulation, at least at the transcript level as p62 
and LC3B levels were similar in both models. Differences 
in autophagy-related proteins and gene expression under 
TTC treatment show an effect of TTC in the autophagic 
machinery regulation involved in prion diseases. Similarly, 
TTC alters/modulates autophagy mechanisms in muscle 
and spinal cord of murine SMA models [35] where TTC 
induces downregulation of p62 and Atg5 as in our assay but, 
in contrast to our results, decreased LC3 and Becn1 levels. 
As mentioned above, the genetic background can be crucial 
in the response of animals to TTC treatment, mainly at the 
transcript level. This or the moment and tissue used for the 
analysis could explain these differences.
The NeuN protein, localized in the nucleus and perinu-
clear cytoplasm of most neurons in the central nervous sys-
tem of mammals, reflects the functional state of these cells 
[63] and therefore is used as a marker of neuronal survival. 
This neuronal marker has been reported to decrease in prion 
infected mice during prion disease due to severe neuronal 
loss [64]. Our results show that NeuN immunolabelling 
was higher in scrapie diseased mice after TTC-injection in 
both mouse lines. Although sometimes mild, this increase 
on neuronal survival could be observed in all brain areas. 
The increase in neuronal survival could be observed in the 
treated group of both lines, but the statistical significance 
was higher in Tg338. The overexpression of  PrPC is known 
to affect several factors, from different molecular pathways 
[65] to strain selection in prion diseases [66]. Moreover, 
 PrPC has been reported to display a neuroprotective role 
[67]. Therefore, Tg338  PrPC overexpression could be affect-
ing not only autophagy mechanisms, as previously proposed, 
but also the response of other survival pathways to TTC 
administration. The fact that neuronal survival was higher in 
the TTC-treated group even though spongiosis was similar in 
TTC-treated and control mice could be related to the reduc-
tion of the apoptosis observed in treated mice. 
The finding that TTC affected apoptosis and autophagy 
and that this was linked to an increase on neuronal survival 
in TTC-treated mice suggests that TTC is able to reduce 
apoptosis and to regulate autophagy. Moreover, the differ-
ences in p62, LC3 and NeuN expression between control and 
Fig. 6  Assessment of p62 expression in Tg338 and C57BL6 prion 
infected mice after TTC intramuscular injection. A Representative 
images of p62 immunostaining in cerebral cortex of mice, where a 
cytoplasmic labeling can be observed. B Evaluation of p62 staining 
in brains of control and treated C57BL6 and Tg338 mice using the 
Image J software in the aforementioned brain areas. Treated mice of 
both lines displayed lower scores for p62 immunolabeling. Evalua-
tion of significant differences was performed using the Mann–Whit-
ney U test (*p < 0.05 and **p < 0.01) and significant differences were 
found in Mobl, Ht, Th, Pc and Fc in C57BL6 mice and in Mobl, Mes, 
Ht, Th, Pc, Sa and Fc in Tg338 mice. C Western Blot for the p62 
protein in the frontal cortex different groups of mice. A single band 
at ~ 62  kDa confirms the specificity of the antibody. β-Actin immu-
nodetection is shown at ~ 42 kDa. Significant differences were found 
between treated and untreated mice in the Tg338 line when using the 
Student’s t test (**p < 0.01)
◂
Fig. 7  Autophagy-related gene expression profiles. mRNA expres-
sion profiles of Atg5, Becn1, Fbxw7 and Gas5 in the thalamus and 
hypothalamus of TTC-treated and controls C57BL6 and Tg338 mice. 
Relative expression levels are expressed as mean ± standard devia-
tion. Normalization of results was performed using the expression 
of Sdha and H6pd housekeeping genes. The expression values were 
determined using the  2−ddCt method and differences between experi-




Fig. 8  Immunohistochemical analyses of NeuN in the brains of TTC-
injected and control Tg338 and C57BL6 mice. A Representative pic-
tures of different staining levels of NeuN immunostaining in cerebral 
cortex of C57BL6 and Tg338 mice, showing a nuclear and perinu-
clear staining in neurons. B Comparison of the evaluation (using the 
Image J software) of the NeuN immunostaining in TTC-injected and 
control groups of Tg338 and C57BL6 lines in medulla oblongata 
(Mobl), mesencephalon (Mes), hypothalamus (Ht), thalamus (Th), 
hippocampus (Hc), septal area/striatum (Sa), parietal cortex (Pc) and 
frontal cortex (Fc). A NeuN immunostaining increase was observed 
in all brain areas of treated mice, both in C57BL6 and Tg338 lines. 
Significant differences were evaluated using the Mann–Whitney U 
test (*p < 0.05 and **p < 0.01) and found in Sa in C57BL6 mice and 
in Mobl, Mes, Ht, Th, Pc, Sa and Fc in Tg338 mice
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TTC-injected groups could be observed in all brain areas, 
suggesting that TTC is able to diffuse to the whole brain.
Currently, there are no effective therapeutic or prophy-
lactic treatments for prion diseases. Given the complex 
pathogenesis of these disorders, a wide variety of thera-
peutic strategies has been proposed, those aiming at reduc-
ing  PrPSc accumulation being of special importance, since 
this protein is the underlying neurotoxic agent [13]. There 
is experimental evidence that the induction of autophagic 
activity through drugs reduces the levels of  PrPSc [6, 68], but 
it has been observed that the administration of these drugs 
once neuroinvasion has already taken place does not cause 
a clear degradation of  PrPSc deposits in the CNS. Thus, it 
is plausible that autophagic regulation after intracerebral 
prion inoculation does not lead to a decrease in  PrPSc depo-
sition. In agreement with this, we observed that, although 
TTC affects autophagy, it does not avoid  PrPSc accumula-
tion. This explains the fact that both TTC-treated and control 
mice developed similar  PrPSc and spongiosis scores, and as 
a result their survival periods were similar. However, given 
the autophagy regulatory characteristics that TTC shows in 
prion disease models, further investigations on TTC effects 
after prion oral or intraperitoneal inoculation or in prion-
infected cultured cells could be useful to elucidate the effects 
of TTC on autophagy in these diseases, and its connection 
with  PrPSc propagation.
In summary, even though TTC has not affected vacuola-
tion or  PrPSc accumulation, it shows neuroprotective proper-
ties through the regulation of autophagic mechanisms and 
reduction of caspase-dependent apoptosis, thus leading to 
an increase of neuronal survival. These preliminary find-
ings reinforce the role of TTC as a regulator of apoptosis 
and autophagy, and more importantly, as a neuroprotective 
molecule.
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